University of California San Francisco

Publications

  1. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Alvarado M, Julian BQ, Ewing C, Wong J, Rose J, Esserman L, Foster R, Mukhtar RA
    Am J Surg. 2025 Mar; 241:116073.; 
    PubMed
  2. Intermediary clip placement to assist accurate axillary lymph node localization.
    Price ER, Vyas S, Lee AY, Wong JM, Joe BN, Ray KM
    Clin Imaging. 2021 May; 73:96-100.; 
    PubMed
  3. Rate of re-excision after breast-conserving surgery for invasive lobular carcinoma.
    Wanis ML, Wong JA, Rodriguez S, Wong JM, Jabo B, Ashok A, Lum SS, Solomon NL, Reeves ME, Garberoglio CA, Senthil M
    Am Surg. 2013 Oct; 79(10):1119-22.; 
    PubMed
  4. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Wong J, Foster R, Mukhtar RA
    Ann Surg Oncol. 2024 Oct; 31(11):7409-7417.; 
    PubMed
  5. Changes in mammographic density following bariatric surgery.
    Hosseini A, Khoury AL, Varghese F, Carter J, Wong JM, Mukhtar RA
    Surg Obes Relat Dis. 2019 Jun; 15(6):964-968.; 
    PubMed
  6. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
    Ye J, Goldhammer N, Vohra P, Warhadpande S, de Castro GC, Rodas CKM, Moasser MM, Ramalingam K, Abe SE, Alvarado M, Ewing C, Goodwin KM, Mukhtar RA, Wong JM, Esserman LJ, Balassanian R, Rosenbluth JM
    Cancer Cytopathol. 2025 11; 133(11):e70052.; 
    PubMed
  7. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA
    Am J Surg. 2022 04; 223(4):699-704.; 
    PubMed
  8. Breast Cancer in the Elderly.
    Varghese F, Wong J
    Surg Clin North Am. 2018 Aug; 98(4):819-833.; 
    PubMed
  9. Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.
    Silverstein J, Wright F, Stanfield D, Chien AJ, Wong JM, Park JW, Blanco A, Van Loon K, Atreya CE
    Oncologist. 2024 09 06; 29(9):e1159-e1168.; 
    PubMed
  10. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA
    Ann Surg Oncol. 2021 May; 28(5):2555-2560.; 
    PubMed
  11. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA
    Ann Surg Oncol. 2023 Oct; 30(11):6401-6410.; 
    PubMed
  12. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators
    NPJ Breast Cancer. 2019; 5:2.; 
    PubMed
  13. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
    Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ
    JAMA Oncol. 2025 Mar 01; 11(3):288-292.; 
    PubMed
  14. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ
    NPJ Breast Cancer. 2021 May 25; 7(1):59.; 
    PubMed
  15. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    Mukhtar RA, Wong JM, Esserman LJ
    J Natl Compr Canc Netw. 2015 Jun; 13(6):737-43.; 
    PubMed
  16. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
    Clelland EN, Quirarte A, Rothschild HT, Kaur M, Mujir F, Record H, Wong JM, Mukhtar RA
    Ann Surg Oncol. 2024 Oct; 31(11):7315-7322.; 
    PubMed
  17. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    Greenwood HI, Wong JM, Mukhtar RA, Alvarado MD, Price ER
    AJR Am J Roentgenol. 2019 10; 213(4):953-957.; 
    PubMed
  18. Sense of Belonging from Celebrated Identity: Getting to Know Interns Through Surgical Grand Rounds.
    Santos-Parker JR, Santos-Parker KS, Hirose K, Wong JM, Sosa JA
    J Surg Educ. 2026 May; 83(5):103914.; 
    PubMed
  19. Utility and Outcomes of Preoperative Screening Breast MRI for Planned Bilateral Prophylactic Mastectomy in High-Risk Patients.
    Taliaferro AS, Price ER, Hayward JH, Wong JM, Balassanian R, Fay JS, Freimanis RI, Joe BN, Lee AY
    AJR Am J Roentgenol. 2022 02; 218(2):241-248.; 
    PubMed
  20. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators
    NPJ Breast Cancer. 2018; 4:26.; 
    PubMed